We provide advice to complement the current
expert consensus on Summit Therapeutics. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Summit Therapeutics income statement, its balance sheet, and the statement of cash flows. Potential Summit Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Summit Therapeutics investors may use each financial statement separately, they are all related. The changes in Summit Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Summit Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Summit Therapeutics
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Summit Therapeutics performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Summit Therapeutics shares is the value that is considered the true value of the share. If
the intrinsic value of Summit is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Summit Therapeutics. Please read more on our
fundamental analysis page.
How effective is Summit Therapeutics in utilizing its assets?
Summit Therapeutics PLC reports assets on its Balance Sheet. It represents the amount of Summit resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Summit Therapeutics aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Biotechnology space. To get a better handle on how balance sheet or income statements item affect Summit volatility, please check the breakdown of all its
fundamentals.
Are Summit Therapeutics Earnings Expected to grow?
The
future earnings power of Summit Therapeutics involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Summit Therapeutics factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Summit Therapeutics
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Summit
expected earnings.
Summit Therapeutics Gross Profit
Summit Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Summit Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Summit Therapeutics Gross Profit growth over the last 10 years. Please check Summit Therapeutics'
gross profit and other
fundamental indicators for more details.
Breaking it down
Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Summit Therapeutics is not uncomon. Institutional investors typically avoid acquiring a high percentage of Summit Therapeutics stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Summit is distributed among investors.
Ownership Allocation
Summit Therapeutics PLC shows a total of two hundred one million three hundred twenty thousand nine hundred ninety-two
outstanding shares. Summit Therapeutics PLC has majority of its outstanding shares owned by
insiders. An
insider is usually defined as a corporate executive, director, member of the board or
institutional investor who own at least 10% of the company outstanding shares. 83.11 % of Summit Therapeutics
outstanding shares that are owned by
insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how much assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
| Retail Investors15.18% | Insiders83.11% | |
| Retail Investors | 15.18 |
| Insiders | 83.11 |
| Institutions | 1.71 |
Will Summit Therapeutics growth be reliable after the gain?
Newest jensen alpha is at 3.44. Summit Therapeutics PLC is displaying above-average volatility over the selected time horizon. Investors should scrutinize Summit Therapeutics PLC independently to ensure intended market timing strategies are aligned with expectations about Summit Therapeutics volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Summit Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Summit Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Conclusion on Summit Therapeutics
Whereas some other companies within the biotechnology industry are still a little expensive, even after the recent corrections, Summit Therapeutics may offer a potential longer-term growth to private investors. The inconsistency in the assessment between current Summit valuation and our trade advice on Summit Therapeutics is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Summit Therapeutics.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Summit Therapeutics PLC. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com